Schrodinger, Inc. (SDGR)

Over the past six months, Schrödinger, Inc.'s stock has experienced significant fluctuations. The 52-week high was $28.47 on February 18, 2025, and the 52-week low was $12.81 on February 6, 2026, with the stock price at $13.49 on February 6, 2026. The stock has decreased by 24.6% since the start of 2026 and 47.45% in the past year. Recent news includes an expected earnings date of February 25, 2026, a business progress update on January 12, 2026, and a collaboration with Eli Lilly and Company announced on January 9, 2026. In December 2025, ARK Invest reportedly purchased SDGR stock. The company reported strong fourth-quarter software results but lowered guidance for FY24 drug discovery revenue.

The demand for Schrödinger, Inc.'s products and services exhibits some seasonality. An increase in hosted revenue is expected to reduce seasonality over time. Drug discovery revenue is generally weighted towards the second half of the year. Historically, February has shown a chance of being a "red month" for the stock.

Schrödinger, Inc. is a life sciences and materials discovery company that uses a physics-based computational platform to accelerate drug discovery and advanced materials design. The company operates in the healthcare sector, specifically in medical information systems and biotechnology. Its business is divided into Software, which provides chemical simulation software, and Drug Discovery, which focuses on building a portfolio of preclinical and clinical programs. Schrödinger's technology is used by various industries globally.

Schrödinger, Inc. serves a worldwide market with 12 global offices and its headquarters are in New York, New York, United States. Revenue distribution includes regions such as APAC, Rest of World, Japan, and Europe.

Schrödinger has a strong brand reputation for its scientific and technological breakthroughs in drug discovery and materials design. It was recognized as one of "America's 100 Most Loved Workplaces" by Newsweek in 2022 and listed among Inc.'s "Best-Led Companies" in 2021. The company has a high customer retention rate of 99% among its partners, and its collaborations with leading pharmaceutical companies underscore its credibility. Its software has been instrumental in the discovery of two FDA-approved drugs, with 15 more in the pipeline.

Schrödinger, Inc. has significant institutional ownership, with 393 institutional owners and shareholders holding 80,791,926 shares, representing approximately 79.05% of the stock. Major institutional owners include BlackRock, Inc., Bill & Melinda Gates Foundation Trust, Vanguard Group Inc., Rubric Capital Management LP, and Sumitomo Mitsui Trust Holdings, Inc. Insiders own about 21.00% of the stock.